A detailed history of Ubs Asset Management Americas Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 189,739 shares of ACAD stock, worth $3.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
189,739
Previous 217,595 12.8%
Holding current value
$3.24 Million
Previous $3.54 Million 17.4%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.14 - $19.14 $421,739 - $533,163
-27,856 Reduced 12.8%
189,739 $2.92 Million
Q2 2024

Aug 13, 2024

BUY
$14.62 - $18.42 $1.44 Million - $1.81 Million
98,252 Added 82.33%
217,595 $3.54 Million
Q1 2024

May 15, 2024

SELL
$17.79 - $30.86 $53,458 - $92,734
-3,005 Reduced 2.46%
119,343 $2.21 Million
Q4 2023

Feb 14, 2024

BUY
$20.78 - $31.77 $74,911 - $114,530
3,605 Added 3.04%
122,348 $3.83 Million
Q3 2023

Nov 13, 2023

SELL
$20.84 - $33.47 $164,052 - $263,475
-7,872 Reduced 6.22%
118,743 $2.47 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $2.07 Million - $2.65 Million
126,615 New
126,615 $2.38 Million
Q3 2022

Nov 14, 2022

SELL
$14.11 - $18.27 $6.93 Million - $8.98 Million
-491,336 Reduced 79.95%
123,201 $0
Q2 2022

Aug 12, 2022

BUY
$13.01 - $27.22 $548,917 - $1.15 Million
42,192 Added 7.37%
614,537 $0
Q1 2022

May 16, 2022

BUY
$20.94 - $27.5 $635,570 - $834,680
30,352 Added 5.6%
572,345 $0
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $1.31 Million - $2.12 Million
78,185 Added 16.86%
541,993 $0
Q3 2021

Nov 15, 2021

SELL
$15.78 - $24.77 $333,415 - $523,365
-21,129 Reduced 4.36%
463,808 $0
Q2 2021

Aug 16, 2021

BUY
$19.4 - $27.42 $1.58 Million - $2.23 Million
81,312 Added 20.15%
484,937 $0
Q1 2021

May 14, 2021

SELL
$25.02 - $54.99 $4.28 Million - $9.42 Million
-171,220 Reduced 29.79%
403,625 $0
Q4 2020

Mar 01, 2021

SELL
$41.04 - $56.79 $610,716 - $845,091
-14,881 Reduced 2.52%
574,845 $0
Q3 2020

Nov 13, 2020

SELL
$36.42 - $57.0 $12 Million - $18.8 Million
-329,928 Reduced 35.88%
589,726 $0
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $5.66 Million - $7.6 Million
144,052 Added 18.57%
919,654 $0
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $2.7 Million - $3.99 Million
-85,195 Reduced 9.9%
775,602 $0
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $27.1 Million - $38.5 Million
749,288 Added 671.95%
860,797 $0
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $154,251 - $305,517
6,942 Added 6.64%
111,509 $0
Q2 2019

Aug 15, 2019

BUY
$23.32 - $28.12 $239,566 - $288,876
10,273 Added 10.89%
104,567 $0
Q1 2019

May 14, 2019

BUY
$16.17 - $27.38 $211,810 - $358,650
13,099 Added 16.13%
94,294 $0
Q4 2018

Feb 13, 2019

BUY
$14.32 - $22.92 $181,105 - $289,869
12,647 Added 18.45%
81,195 $0
Q3 2018

Nov 14, 2018

BUY
$13.03 - $21.81 $247 - $414
19 Added 0.03%
68,548 $0
Q2 2018

Aug 14, 2018

SELL
$15.07 - $22.34 $8.18 Million - $12.1 Million
-543,117 Reduced 88.8%
68,529 $0
Q1 2018

May 14, 2018

SELL
$22.47 - $32.33 $6.24 Million - $8.98 Million
-277,730 Reduced 31.23%
611,646 $0
Q4 2017

Feb 09, 2018

BUY
$26.84 - $39.14 $2.78 Million - $4.05 Million
103,583 Added 13.18%
889,376 $0
Q3 2017

Nov 13, 2017

BUY
$29.49 - $38.37 $23.2 Million - $30.2 Million
785,793
785,793 $0

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.